Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prelude Therapeutics (PRLD) Common Equity (2024 - 2025)

Prelude Therapeutics' Common Equity history spans 2 years, with the latest figure at $68.6 million for Q4 2025.

  • For Q4 2025, Common Equity fell 47.79% year-over-year to $68.6 million; the TTM value through Dec 2025 reached $68.6 million, down 47.79%, while the annual FY2025 figure was $68.6 million, 47.79% down from the prior year.
  • Common Equity for Q4 2025 was $68.6 million at Prelude Therapeutics, up from $58.5 million in the prior quarter.
  • Across five years, Common Equity topped out at $210.7 million in Q1 2024 and bottomed at $58.5 million in Q3 2025.